AbbVie exploited drug patent system to extend market monopoly, abused orphan drug protections to block competition, US House panel finds
MLex Summary: AbbVie Inc. has repeatedly raised prices of two of its blockbuster drugs Humira (adalimumab) and Imbruvica (ibrutinib), with the price hikes contributing to billions of dollars in corporate profits...To view the full article, register now.
Already a subscriber? Click here to view full article